mProX™ Human ICOSLG Stable Cell Line

Product Information

Target Family

Immune Checkpoint

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;Mouse glioma cancer-initiating cells

Target Classification

Immune Checkpoint Cell Lines

Target Research Area

Immunology Research

Related Diseases

Combined Immunodeficiency; B Cell Deficiency

Gene ID

Human:23308

UniProt ID

Human:O75144

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

ICOSLG, a member of the B7 protein family, has been studied in various contexts. In oral squamous cell carcinoma (OSCC), ICOSLG expression was found in tumor cells, cancer-associated fibroblasts, and tumor infiltrating lymphocytes. High levels of ICOSLG in OSCC were associated with advanced disease stage and poor survival outcomes. Additionally, ICOSLG was correlated with other immune checkpoint molecules and could be used as a marker for patient stratification in precision immunotherapy. In metastatic urothelial carcinoma (mUC) treated with pembrolizumab, the presence of tertiary lymphoid structures (TLS) and a lower neutrophil-lymphocyte ratio (NLR) were associated with improved treatment outcomes. ICOSLG expression was significantly increased in tumors with a lower NLR. In ovarian cancer, TRPM2 expression was correlated with poor prognosis and immune infiltration. TRPM2 may serve as a prognostic factor and a potential immunotherapy target in ovarian cancer. In a pan-cancer cohort, T-cell priming transcriptomic markers (TPMs) were analyzed for their correlation with immunotherapy biomarkers. Diverse expression patterns of TPMs were observed, and individualized selection of patients based on TPM expression profiles may optimize immunotherapy. Finally, genetic impacts on DNA methylation were investigated, revealing that methylation levels at a significant proportion of CpGs are affected by SNPs. Co-localization analyses identified associations between genetic effects on DNA methylation and various human traits, including disease-related genes. These findings contribute to our understanding of regulatory genomic processes and can aid in prioritizing GWAS variants for functional follow-ups.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human ICOSLG Stable Cell Line (S01YF-1023-PY169). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Jordan Johnson (Verified Customer)

What is the prognostic significance of ICOSLG in glioblastoma? Mar 25 2022

chat Patrick Liam (Creative Biolabs Scientific Support)

High plasma IL-8 and low ICOSLG at surgery are associated with short overall survival in newly diagnosed patients with glioblastoma. Mar 25 2022

chat Peyton Jones (Verified Customer)

How does ICOSLG influence immune responses at epithelial barriers? Apr 18 2021

chat Patrick Liam (Creative Biolabs Scientific Support)

ICOSLG plays a critical role in human immunity at mucocutaneous barriers, mediating epithelial host defenses. Apr 18 2021

Published Data

Fig.1 In a syngeneic brain tumor model, the in vivo effects of ICOSLG knockdown were examined.

Mouse RasR2 GSCs were subjected to stable induction of shICOSLG or shNT expression, and representative flow cytometry results were obtained to demonstrate the expression of ICOSLG. The MFI-R values, denoting mean fluorescence intensity ratios, were indicated in each panel.

Ref: Iwata, Ryoichi, et al. "ICOSLG-mediated regulatory T-cell expansion and IL-10 production promote progression of glioblastoma." Neuro-oncology 22.3 (2020): 333-344.

Pubmed: 31634400

DOI: 10.1093/neuonc/noz204

Research Highlights

Dong, Yuexin. et al. "ICOSLG-associated immunological landscape and diagnostic value in oral squamous cell carcinoma: a prospective cohort study." Frontiers in cell and developmental biology, 2023.
The goal of the current research project is to examine the impact of mindfulness training on reducing stress among college students. A randomized controlled trial will be carried out, with one group receiving an 8-week mindfulness intervention and the other serving as a control. Pre- and post-intervention evaluations, including self-report surveys and physiologic measurements, will be utilized to assess the effectiveness of the intervention. Overall, this study seeks to shed light on the potential advantages of mindfulness for college students and guide future intervention approaches.
Dong, Yuexin. et al. "ICOSLG-associated immunological landscape and diagnostic value in oral squamous cell carcinoma: a prospective cohort study." Frontiers in cell and developmental biology, 2023.
Pubmed: 37842091 DOI: 10.3389/fcell.2023.1257314

Komura, Kazumasa. et al. "Tertiary lymphoid structure and neutrophil-lymphocyte ratio coordinately predict outcome of pembrolizumab." Cancer science, 2023.
New evidence has indicated a potential correlation between the presence of tertiary lymphoid structures (TLS) and neutrophil-lymphocyte ratio (NLR) in peripheral blood and the response to checkpoint inhibitors (CPIs) in metastatic urothelial carcinoma (mUC) patients. In this study, 50 platinum-refractory mUC patients were treated with pembrolizumab and their outcomes were analyzed based on TLS and NLR status. Results showed that patients with TLS had significantly better overall and progression-free survival in the lower NLR group. Transcriptomic analysis also revealed differences in immune-checkpoint gene expression and keratin levels in these patients. These findings suggest that the presence of TLS may play a role in determining the treatment response to CPIs in a subset of mUC patients with a lower NLR.
Komura, Kazumasa. et al. "Tertiary lymphoid structure and neutrophil-lymphocyte ratio coordinately predict outcome of pembrolizumab." Cancer science, 2023.
Pubmed: 37752769 DOI: 10.1111/cas.15976